One could argue that CMS is restricting coverage of a particular instance of an accelerated approval and a set of potential approvals for a narrowly defined sub-class of beta amyloid-directed monoclonal antibodies. And this particular decision has no universal implications outside of this sub-class.
Subscribe to:
Post Comments (Atom)
< + > Stop Waiting on Mandates: CMS Challenges Health IT to Act Now
“We’re the government and we’re here to help.” That’s a common punchline, but based on recent IT announcements from CMS, this line may turn ...
No comments:
Post a Comment